Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16732414 | 1.00 | KMT2A (0.55) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL21540243 | 1.00 | KMT2A (0.55) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL19720285 | 0.93 | KMT2A (0.50) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535467 | 0.93 | KMT2A (0.50) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535474 | 0.87 | KMT2A (0.44) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL31371076 | 0.87 | TSHR (0.48) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL4621117 | 0.86 | TSHR (0.56) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL5471268 | 0.84 | TSHR (0.54) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL13535468 | 0.83 | TSHR (0.48) | KMT2ATSHRCA1CA2CA7 | |
| SCHEMBL12408480 | 0.82 | TSHR (0.52) | KMT2ATSHRCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20170281667-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | AYUVIS RESEARCH, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| CN-102267878-A | Method for preparing 1,3-diaroxy or alkoxy-2-propanol compound | — | 2011-12-07 | — | — | CN | disclosed |
| US-7648651-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2010-01-19 | — | — | US | disclosed |
| US-7648651-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2010-01-19 | — | — | US | disclosed |
| US-7648651-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090093588-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093588-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093588-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2009-04-09 | — | — | US | disclosed |
| US-7507355-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2009-03-24 | — | — | US | disclosed |
| US-7507355-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2009-03-24 | — | — | US | disclosed |
| US-7507355-B2 | Solvent composition | ADEKA CORPORATION (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20070257233-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070257233-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070257233-A1 | Solvent Composition | ADEKA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1808223-A1 | SOLVENT COMPOSITION | Adeka Corporation (JP) | 2007-07-18 | — | — | EP | disclosed |
| EP-1808223-A1 | SOLVENT COMPOSITION | Adeka Corporation (JP) | 2007-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281667-A1 | NOVEL COMPOSITIONS AND THERAPEUTIC METHODS | RB1, CD47, FLT1 | KMT2A 3915/4885TSHR 2494/4885CA1 3070/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | KMT2A 4481/4885TSHR 3021/4885CA1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.